UnitedHealth Group CEO Andrew Witty Resigns
On May 1, 2024, UnitedHealth Group’s CEO Andrew Witty appeared before the Senate Finance Committee for a hearing titled “Hacking America’s Health Care: Assisting and What’s Next,” held in the Dirksen Building, Washington, DC.
Witty announced his unexpected resignation on Tuesday, citing “personal reasons.” This news led to a nearly 10% drop in the company’s stock during pre-market trading, and forecasts for 2025 have been halted. Following Witty’s departure, he will serve as a Senior Advisor to Stephen Hemsley, who was the company’s CEO from 2006 to 2017.
Hemsley expressed gratitude for Witty’s leadership during challenging times. The company also noted that the decision to halt guidance was influenced by rising healthcare costs affecting shares of other insurance providers. For instance, CVS Health’s stock fell nearly 3%, while eLlevance Health also saw a decline of over 3%. Humana’s shares dropped by more than 2%, and Cigna’s stock was down over 1%.
Witty, who took the helm at UnitedHealth in 2021 after nearly a decade leading GlaxoSmithKline, faced significant challenges, including government investigations and a cybersecurity breach, alongside rising healthcare costs and public backlash following the murder of Brian Thompson, head of UnitedHealthcare.
As he previously noted, the U.S. healthcare system has its flaws and needs reform, a point that was made clear in December. Recently, UnitedHealth Group announced a partial halt to its projections due to unexpectedly high medical costs for new enrollees in its private Medicare plan, but added that care activities will expand more rapidly than initially anticipated.
This follows a recent significant cut to the company’s annual profit forecast, driven by increasing health costs impacting Medicare Advantage plans. The industry as a whole has struggled with rising hospital admissions and delays in procedures, a lingering consequence of the Covid-19 pandemic.
Notably, the company reported its first earnings miscalculation since 2008, resulting in a stock decline and wiping out nearly $190 billion in market capitalization. Nevertheless, Hemsley’s return could be seen as a positive for investors; he has been pivotal in transforming the organization into a $400 billion healthcare conglomerate that encompasses private insurance, pharmacy benefits, and medical data management.
“UnitedHealth Group is well-positioned for growth as we focus on advancing healthcare improvements,” Hemsley stated, aiming to return to long-term growth targets of 13-16%. The company anticipates a return to growth by 2026.
